Senators try to clear path for new antibiotics

Share this article:

Sens. Richard Blumenthal (D-CT) and Bob Corker (R-TN) have introduced the Generating Antibiotic Initiatives Now (GAIN) Act to spur antibiotic development to fight the spread of antibiotic-resistant bacteria.

“Superbugs or mutant germs resistant to present antibiotics are a growing public health horror,” Blumenthal said. “The threat of these new resistant bacterial infections, particularly threatening to children, seniors, and our returning troops, requires innovative antibiotics. Incentives for research and development and fast-track FDA review are needed to stop these bacteria and infections from spreading.”

Blumenthal said that antibiotic resistance increasingly affects troops back from Iraq and Afghanistan, many of whom have been exposed to a highly resistant and contagious strain of Acinetobacter bacteria. Some 89% of infections from mutant strains of Acinetobacter are resistant to at least three classes of antibiotics and 15% resist all forms of treatment, he said.

The GAIN Act has been endorsed by 39 groups, including the National Military Vets Alliance, American Medical Association and St. Jude's Children's Research Hospital.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?